“HDAC Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HDAC Inhibitor Market.
The HDAC Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ HDAC Inhibitor Pipeline Analysis
Some of the key takeaways from the HDAC Inhibitor Pipeline Report:
- HDAC Inhibitor Companies across the globe are diligently working toward developing novel HDAC Inhibitor treatment therapies with a considerable amount of success over the years.
- HDAC Inhibitor companies working in the treatment market are Roche, Takeda, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others, are developing therapies for the HDAC Inhibitor treatment
- Emerging HDAC Inhibitor therapies such as – Givinostat, Research programme: histone deacetylase inhibitors, ACS 33, MG 4915, AP CANC04, DAC 0060, KAR 2581, Abexinostat, Remetinostat, Mocetinostat, Quisinostat, and others are expected to have a significant impact on the HDAC Inhibitor market in the coming years.
- On January 2024, Xynomic Pharmaceuticals, Inc announced results of an Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
- On March 2024, Novartis announced results of an Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies
- On October 2023, Celgene announced results of a Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
- In March 2021, AlloVir initiated a Phase III study to evaluate ALVR105 (Viralym-M); an allogeneic, off the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus
- In October 2021, the US Food and drug administration (FDA) granted Orphan Drug Designation (ODD) to posoleucel (ViralymM, ALVR105) for the treatment of virus-associated hemorrhagic cystitis (HC). This Orphan Drug Designation acknowledges the urgent need for new treatment options for patients who have undergone hematopoietic stem cell transplantation and are at risk for developing viral infections and hemorrhagic cystitis
HDAC Inhibitor Overview
HDAC inhibitors are a class of pharmaceutical compounds that target enzymes called histone deacetylases (HDACs). HDACs play a crucial role in gene expression regulation by removing acetyl groups from histone proteins, which are involved in packaging DNA and influencing its accessibility to transcription factors and other proteins.
By inhibiting HDAC activity, HDAC inhibitors alter the acetylation status of histones, leading to changes in gene expression patterns. This can result in a wide range of biological effects, including anti-cancer, anti-inflammatory, and neuroprotective activities. HDAC inhibitors have gained significant attention as potential therapeutic agents for various diseases, particularly cancer.
Get a Free Sample PDF Report to know more about HDAC Inhibitor Pipeline Therapeutic Assessment @ https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight
HDAC Inhibitor Route of Administration
HDAC Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
HDAC Inhibitor Molecule Type
Products have been categorized under various Molecule types, such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
HDAC Inhibitor Pipeline Therapeutics Assessment
- HDAC Inhibitor Assessment by Product Type
- HDAC Inhibitor By Stage and Product Type
- HDAC Inhibitor Assessment by Route of Administration
- HDAC Inhibitor By Stage and Route of Administration
- HDAC Inhibitor Assessment by Molecule Type
- HDAC Inhibitor by Stage and Molecule Type
DelveInsight's HDAC Inhibitor Pipeline Report covers around 50+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further HDAC Inhibitor product details are provided in the report. Download the HDAC Inhibitor pipeline report to learn more about the emerging HDAC Inhibitor therapies @ https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight
HDAC Inhibitor Pipeline Analysis:
The HDAC Inhibitor pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of HDAC Inhibitor with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HDAC Inhibitor Treatment.
- HDAC Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- HDAC Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HDAC Inhibitor market.
Download Sample PDF Report to know more about HDAC Inhibitor drugs and therapies @ https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight
HDAC Inhibitor Pipeline Market Drivers
One of the major HDAC Inhibitor market drivers for HDAC inhibitors is their potential in cancer treatment. These inhibitors have demonstrated efficacy in preclinical and clinical studies, showing the ability to inhibit tumor growth, induce cell death, and sensitize cancer cells to other therapies. The demand for novel cancer treatments drives the interest in HDAC inhibitors.
HDAC Inhibitor Pipeline Market Barriers
However Safety and Tolerability Concerns, Limited Clinical Success, Drug Specificity and Selectivity and other factors are creating obstacles in the HDAC Inhibitor Market growth.
Scope of HDAC Inhibitor Pipeline Drug Insight
- Coverage: Global
- Key HDAC Inhibitor Companies: Roche, Takeda, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others
- Key HDAC Inhibitor Therapies: Givinostat, Research programme: histone deacetylase inhibitors, ACS 33, MG 4915, AP CANC04, DAC 0060, KAR 2581, Abexinostat, Remetinostat, Mocetinostat, Quisinostat, and others.
- HDAC Inhibitor Therapeutic Assessment: HDAC Inhibitor current marketed and HDAC Inhibitor emerging therapies
- HDAC Inhibitor Market Dynamics: HDAC Inhibitor market drivers and HDAC Inhibitor market barriers
Request for Sample PDF Report for HDAC Inhibitor Pipeline Assessment and clinical trials @ https://www.delveinsight.com/sample-request/hdac-inhibitor-pipeline-insight
Table of Contents
1. HDAC Inhibitor Report Introduction
2. HDAC Inhibitor Executive Summary
3. HDAC Inhibitor Overview
4. HDAC Inhibitor- Analytical Perspective In-depth Commercial Assessment
5. HDAC Inhibitor Pipeline Therapeutics
6. HDAC Inhibitor Late Stage Products (Phase II/III)
7. HDAC Inhibitor Mid Stage Products (Phase II)
8. HDAC Inhibitor Early Stage Products (Phase I)
9. HDAC Inhibitor Preclinical Stage Products
10. HDAC Inhibitor Therapeutics Assessment
11. HDAC Inhibitor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. HDAC Inhibitor Key Companies
14. HDAC Inhibitor Key Products
15. HDAC Inhibitor Unmet Needs
16 . HDAC Inhibitor Market Drivers and Barriers
17. HDAC Inhibitor Future Perspectives and Conclusion
18. HDAC Inhibitor Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
